Plexxikon

Biotechnology Research • South San Francisco, California, United States • 11-20 Employees

Company overview

Headquarters	329 Oyster Pt. Blvd, South San Francisco, California 94080, US
Phone number	+15106474000
Websites	plexxikon.com daiichisankyo.com
NAICS	541714
SIC	283
Employees	11-20
Socials

Key Contact at Plexxikon

Chao Zhang

Senior Vice President, Research

Plexxikon Email Formats

Plexxikon uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About Plexxikon

Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikon’s platform enables the design of highly selective and targeted medicines, supporting the company’s broader strategy to develop personalized medicines. In 2005, Plexxikon scientists discovered ZELBORAF® (vemurafenib) tablets, formerly known as PLX4032, and initiated the first clinical trial in 2006. Together with its partner Roche, Plexxikon co-developed this mutation-specific medicine, in less than five years. A companion diagnostic used to determine ZELBORAF treatment eligibility was approved at the same time. ZELBORAF has been approved in over 40 countries worldwide. Plexxikon's demonstrated capability in discovery and early development, as well as its diverse pipeline, uniquely positions the company to develop multiple commercial franchises for different therapeutic indications, and create significant value for Plexxikon and its collaborators. Plexxikon's novel discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnerships that support later stage development, have been key drivers of the company's success since it began operations in 2001.

Plexxikon revenue & valuation

Annual revenue	$14,000,000
Revenue per employee	$995,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$44,600,000
Total funding	$7,500,000